Evofem Biosciences
12400 High Bluff Drive
Suite 600
San Diego
California
92130
Tel: 858-550-1900
Fax: 844-828-2010
Website: http://www.evofem.com/
Email: info@evofem.com
196 articles about Evofem Biosciences
-
Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
5/22/2018
The shares and pre-funded warrants are being sold at a public offering price of $4.69 per share and $4.68 per pre-funded warrant
-
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
-
Evofem Biosciences Announces Proposed Public Offering of Common Stock
4/24/2018
Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offering of $40.0 million of its common stock
-
Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
2/21/2018
Evofem Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® vaginal gel for the prevention of urogenital chlamydia in women.
-
The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women.
-
Evofem Biosciences Completes Enrollment of Phase III Contraceptive Trial of Amphora Ahead of Schedule
2/15/2018
Trial data is expected in the first quarter of 2019.
-
Evofem Biosciences Announces First Patient Enrolled in Phase Ib/III STI Trial of Amphora and Expects Phase III Contraceptive Clinical Trial Data First Quarter 2019
1/23/2018
Evofem Biosciences today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.
-
Evofem Announces Closing of Merger With Neothetics
1/18/2018
The merged company will operate as Evofem Biosciences and will focus on the continued development and commercialization of women's healthcare products.
-
Neothetics and Evofem Biosciences Announce Merger Agreement to Create Women’s Health Company
10/17/2017
The merger will position the combined company with an opportunity to become a leading women's health company that develops and commercializes novel products.
-
Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy
7/28/2017
-
Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph
8/17/2016
-
Evofem Secures $25.0 Million In Series D Funding
8/4/2016
-
Evofem CEO, Saundra Pelletier, To Address The Cavendish Global Health Impact Forum At BIOCOM On Innovations In Reproductive Health Care Around The Globe
6/16/2016
-
Evofem And WomanCare Global To Attend Women Deliver 2016
5/16/2016
-
Evofem Files IND For Evaluation Of Prevention Of Recurrence Of Bacterial Vaginosis
3/31/2016
-
Evofem And DKT To Develop Coated Condom
2/9/2016